Securing Pharma Supply Chains – Why We Invested in AltiusHub
The Problem: A $200 Billion Counterfeit Crisis
Counterfeit medicines make up over 10% of the global pharmaceutical market, causing $200 billion in losses annually and, more importantly, endangering lives. Governments worldwide are introducing strict compliance regulations—US DSCSA, EU FMD, UAE Tatmeen, India’s iVeda and the like—to ensure drug authenticity and supply chain security.
Legacy tracking systems are slow, fragmented, and expensive, making compliance a challenge for pharmaceutical manufacturers, distributors, and pharmacies. With India’s pharma exports growing rapidly, ensuring visibility, efficiency, and compliance across the supply chain is more critical than ever, especially when it comes to ensuring pharma supply chain transparency and resilience.
Why AltiusHub Stood Out to Us
When we came across AltiusHub, we immediately saw a clear, technology-driven solution to this growing problem. Their unified SaaS platform tackles pharmaceutical compliance, pharma serialization, and supply chain visibility in real-time without the need for any manual intervention—something legacy systems struggle to do.
What sets AltiusHub apart is its ability to automate compliance and reporting, eliminating the need for manual data entry, reducing errors, and saving valuable time for pharmaceutical companies. The platform enables real-time data transmission to country-specific compliance platforms, ensuring seamless regulatory alignment across global markets. With 10x faster serialization than existing solutions, AltiusHub improves manufacturing facilities’ speed of operations and enables seamless tracking of drugs from production to final sale at scale. Additionally, its system integrates effortlessly with ERP and other manufacturing and supply chain platforms without causing disruptions, making adoption smooth for enterprises. Beyond operational efficiency, AltiusHub delivers significant cost benefits, reducing compliance expenses and minimizing supply chain risks by 25-30%, making it a transformative force in pharmaceutical track and trace solutions and counterfeit drugs prevention for drug supply chain security
Why We Invested
At Endiya Partners, we back early-stage product startups solving large-scale, industry-defining problems. The pharma track & trace market is growing fast—expected to hit $4.7 billion by 2027—and AltiusHub is positioned to lead this transformation.
India, the third-largest drug producer globally, has no homegrown track & trace leader. AltiusHub is changing that. With their SaaS-first approach, deep expertise in pharma compliance, and scalable automation, they’re creating a new gold standard for the industry.
Technology alone isn’t enough—great execution is key. Founders, Siddharth Reddy and Abiram Vijayakumar, bring deep industry expertise, a strong customer-first approach, and a proven ability to scale innovative solutions. They understand the complexity of pharma regulations and are building a future-ready solution for a highly regulated and high-growth industry.
What’s Next?
With our $2.25 million investment, AltiusHub is scaling its engineering, compliance automation, and market reach. We believe the future of pharma supply chains must be smarter, safer, and fully compliant—and AltiusHub is making that future a reality.
